Humacyte Balance Sheet Health
Financial Health criteria checks 5/6
Humacyte has a total shareholder equity of $26.2M and total debt of $0.0, which brings its debt-to-equity ratio to 0%. Its total assets and total liabilities are $161.5M and $135.3M respectively.
Key information
0%
Debt to equity ratio
US$0
Debt
Interest coverage ratio | n/a |
Cash | US$115.51m |
Equity | US$26.15m |
Total liabilities | US$135.31m |
Total assets | US$161.47m |
Recent financial health updates
Recent updates
Humacyte: Pioneering Vascular Solutions With High-Stakes Potential
Jul 17Shareholders Will Probably Not Have Any Issues With Humacyte, Inc.'s (NASDAQ:HUMA) CEO Compensation
Jun 05Humacyte: A Strong Opportunity In Wound Healing - A 'Buy' Before Price Gets Too High
May 14Will Humacyte (NASDAQ:HUMA) Spend Its Cash Wisely?
Feb 14Humacyte: Intriguing Potential
Oct 13Humacyte GAAP EPS of $0.35, revenue of $1.3M
Aug 12Financial Position Analysis
Short Term Liabilities: HUMA's short term assets ($117.9M) exceed its short term liabilities ($14.1M).
Long Term Liabilities: HUMA's short term assets ($117.9M) do not cover its long term liabilities ($121.2M).
Debt to Equity History and Analysis
Debt Level: HUMA is debt free.
Reducing Debt: HUMA had no debt 5 years ago.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss-making in the past, we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: HUMA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: HUMA has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 4.7% each year.